Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.

Talha Badar, Selina M. Luger, Mark R Litzow

Blood blood.2023022921.

https://doi.org/10.1182/blood.2023022921

Published: 2024

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2023-188328

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Outcomes of Patients Receiving Intensive Therapy for Acute Myeloid Leukemia Relapsed after/Refractory to Frontline Less-Intensive Therapy

Rohan Achar, Benjamin J. McCormick, Emily Dworkin, Emily Geramita, Annie Im, Anand Ashwin Patel, Talha Badar, Rory M. Shallis

Blood (2023) 142 (Supplement 1): 5859.

https://doi.org/10.1182/blood-2023-179336

Published: 2023

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood (2023) 142 (Supplement 1): 591.

https://doi.org/10.1182/blood-2023-178837

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy

Alexandra E. Rojek, Benjamin J. McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza, Rohan Achar, Rory M. Shallis, Danielle Bradshaw, Meaghan Standridge, Vamsi K. Kota, Talha Badar, Anand Ashwin Patel

Blood (2023) 142 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2023-185163

Published: 2023

Journal Articles

Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes

Talha Badar, Terra L Lasho, Yael Kusne, Ludovica Marando, Abhishek A Mangaonkar, Christy M Finke, James M. Foran, Aref Al-Kali, Hassan Alkhateeb, Naseema Gangat, Rong He, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2023-187310

Published: 2023

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Guru Subramanian Guru Murthy, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Adam S Duvall, Bijal D. Shah, Arielle Baim, Tyce Kearl, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2023-187721

Published: 2023

Journal Articles

Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation

Talha Badar, Ravi Narra, Alice Mims, Rory M. Shallis, Guilherme Sacchi De Camargo Correia, Cameron Hunter, Vamsi K. Kota, Shreya Desai, Anand Ashwin Patel, Adam S Duvall, Neil Palmisiano, Emily K Curran, Omer Zulfa, Anjali S. Advani, Ehab L. Atallah, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 1464.

https://doi.org/10.1182/blood-2023-188188

Published: 2023

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Guru Subramanian Guru Murthy, Bijal D. Shah, Adam S Duvall, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Tyce Kearl, Arielle Baim, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2023-187468

Published: 2023

Journal Articles

T-Cells Immune Cluster Analysis Using Cytof Identifies Unique Patient Subgroups with TP53 Mutation and Predicts Complete Remission (CR) in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax Plus Hypomethylating Agent Therapy

Talha Badar, Keith Knutson, James M. Foran, Naseema Gangat, Kevin Pavelko, Scott H. Kaufmann, Mark R. Litzow, Hemant S. Murthy, Davitte Cogen, Margaret Ushman, Arini Arsana, Aref Al-Kali, Hassan Alkhateeb, Ayalew Tefferi, Mrinal M. Patnaik, Mithun V Shah

Blood (2023) 142 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2023-185654

Published: 2023

Journal Articles

Genetic Complementation Studies Reveal That Many Disease-Associated DDX41 Variants Do Not Cause Loss of Protein Function

Timothy Chlon, Emily Stepanchick, Christy M Finke, Terra L Lasho, Talha Badar, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4104.

https://doi.org/10.1182/blood-2023-181881

Published: 2023

Journal Articles

Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2023-177758

Published: 2023

Journal Articles

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Animesh D. Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2023-185185

Published: 2023

Journal Articles

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Talha Badar, Ehab L. Atallah, Rory M. Shallis, Anand Ashwin Patel, Guilherme Sacchi De Camargo Correia, Aaron D. Goldberg, Antoine Saliba, Jan Philipp Bewersdorf, Adam S Duvall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Vamsi K. Kota, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 592.

https://doi.org/10.1182/blood-2023-184626

Published: 2023

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Outcomes of Patients Receiving Intensive Therapy for Acute Myeloid Leukemia Relapsed after/Refractory to Frontline Less-Intensive Therapy

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy

Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

T-Cells Immune Cluster Analysis Using Cytof Identifies Unique Patient Subgroups with TP53 Mutation and Predicts Complete Remission (CR) in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax Plus Hypomethylating Agent Therapy

Genetic Complementation Studies Reveal That Many Disease-Associated DDX41 Variants Do Not Cause Loss of Protein Function

Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only